Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection

Stephen D W Beck, Richard Foster, Richard Bihrle, Michael Koch, Gregory R. Wahle, John P. Donohue

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: We reviewed the records of 15 patients with metastatic germ cell cancer who underwent aortic resection and replacement during post-chemotherapy retroperitoneal lymph node dissection to determine the morbidity and the therapeutic benefit. Materials and Methods: Between 1970 and 1998, 1,250 patients underwent post-chemotherapy retroperitoneal lymph node dissection. Our retrospective review revealed that 15 patients underwent aortic replacement at that operation. Results: In addition to aortic replacement 11 patients underwent 15 additional procedures, including nephrectomy in 7, vena caval resection in 3, pulmonary resection in 1, small bowel resection in 2, 1 hepatic resection in 1 and L4 vertebrectomy in 1. No patient had necrosis as the only pathological condition. Three patients (20%) had teratoma and 12 (80%) had viable tumor in the retroperitoneal specimen. All 4 patients who underwent post-chemotherapy retroperitoneal lymph node dissection and aortic replacement after induction chemotherapy alone have no evidence of disease. Only 1 of the 11 patients who received salvage chemotherapy with or without previous post-chemotherapy retroperitoneal lymph node dissection have no evidence of disease. Overall 33% of the patients have no evidence of disease. There were no graft related complications. Conclusions: Aortic resection at post-chemotherapy retroperitoneal lymph node dissection is justified based on therapeutic benefit and morbidity.

Original languageEnglish
Pages (from-to)1517-1520
Number of pages4
JournalJournal of Urology
Volume165
Issue number5 I
StatePublished - 2001

Fingerprint

Lymph Node Excision
Drug Therapy
Morbidity
Venae Cavae
Induction Chemotherapy
Germ Cell and Embryonal Neoplasms
Teratoma
Nephrectomy
Necrosis
Transplants
Lung
Liver
Therapeutics

Keywords

  • Aorta
  • Germinoma
  • Lymph nodes
  • Metastases
  • Testis

ASJC Scopus subject areas

  • Urology

Cite this

Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. / Beck, Stephen D W; Foster, Richard; Bihrle, Richard; Koch, Michael; Wahle, Gregory R.; Donohue, John P.

In: Journal of Urology, Vol. 165, No. 5 I, 2001, p. 1517-1520.

Research output: Contribution to journalArticle

Beck, Stephen D W ; Foster, Richard ; Bihrle, Richard ; Koch, Michael ; Wahle, Gregory R. ; Donohue, John P. / Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. In: Journal of Urology. 2001 ; Vol. 165, No. 5 I. pp. 1517-1520.
@article{31e2b4506a6745d9a595f9e114e95c99,
title = "Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection",
abstract = "Purpose: We reviewed the records of 15 patients with metastatic germ cell cancer who underwent aortic resection and replacement during post-chemotherapy retroperitoneal lymph node dissection to determine the morbidity and the therapeutic benefit. Materials and Methods: Between 1970 and 1998, 1,250 patients underwent post-chemotherapy retroperitoneal lymph node dissection. Our retrospective review revealed that 15 patients underwent aortic replacement at that operation. Results: In addition to aortic replacement 11 patients underwent 15 additional procedures, including nephrectomy in 7, vena caval resection in 3, pulmonary resection in 1, small bowel resection in 2, 1 hepatic resection in 1 and L4 vertebrectomy in 1. No patient had necrosis as the only pathological condition. Three patients (20{\%}) had teratoma and 12 (80{\%}) had viable tumor in the retroperitoneal specimen. All 4 patients who underwent post-chemotherapy retroperitoneal lymph node dissection and aortic replacement after induction chemotherapy alone have no evidence of disease. Only 1 of the 11 patients who received salvage chemotherapy with or without previous post-chemotherapy retroperitoneal lymph node dissection have no evidence of disease. Overall 33{\%} of the patients have no evidence of disease. There were no graft related complications. Conclusions: Aortic resection at post-chemotherapy retroperitoneal lymph node dissection is justified based on therapeutic benefit and morbidity.",
keywords = "Aorta, Germinoma, Lymph nodes, Metastases, Testis",
author = "Beck, {Stephen D W} and Richard Foster and Richard Bihrle and Michael Koch and Wahle, {Gregory R.} and Donohue, {John P.}",
year = "2001",
language = "English",
volume = "165",
pages = "1517--1520",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5 I",

}

TY - JOUR

T1 - Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection

AU - Beck, Stephen D W

AU - Foster, Richard

AU - Bihrle, Richard

AU - Koch, Michael

AU - Wahle, Gregory R.

AU - Donohue, John P.

PY - 2001

Y1 - 2001

N2 - Purpose: We reviewed the records of 15 patients with metastatic germ cell cancer who underwent aortic resection and replacement during post-chemotherapy retroperitoneal lymph node dissection to determine the morbidity and the therapeutic benefit. Materials and Methods: Between 1970 and 1998, 1,250 patients underwent post-chemotherapy retroperitoneal lymph node dissection. Our retrospective review revealed that 15 patients underwent aortic replacement at that operation. Results: In addition to aortic replacement 11 patients underwent 15 additional procedures, including nephrectomy in 7, vena caval resection in 3, pulmonary resection in 1, small bowel resection in 2, 1 hepatic resection in 1 and L4 vertebrectomy in 1. No patient had necrosis as the only pathological condition. Three patients (20%) had teratoma and 12 (80%) had viable tumor in the retroperitoneal specimen. All 4 patients who underwent post-chemotherapy retroperitoneal lymph node dissection and aortic replacement after induction chemotherapy alone have no evidence of disease. Only 1 of the 11 patients who received salvage chemotherapy with or without previous post-chemotherapy retroperitoneal lymph node dissection have no evidence of disease. Overall 33% of the patients have no evidence of disease. There were no graft related complications. Conclusions: Aortic resection at post-chemotherapy retroperitoneal lymph node dissection is justified based on therapeutic benefit and morbidity.

AB - Purpose: We reviewed the records of 15 patients with metastatic germ cell cancer who underwent aortic resection and replacement during post-chemotherapy retroperitoneal lymph node dissection to determine the morbidity and the therapeutic benefit. Materials and Methods: Between 1970 and 1998, 1,250 patients underwent post-chemotherapy retroperitoneal lymph node dissection. Our retrospective review revealed that 15 patients underwent aortic replacement at that operation. Results: In addition to aortic replacement 11 patients underwent 15 additional procedures, including nephrectomy in 7, vena caval resection in 3, pulmonary resection in 1, small bowel resection in 2, 1 hepatic resection in 1 and L4 vertebrectomy in 1. No patient had necrosis as the only pathological condition. Three patients (20%) had teratoma and 12 (80%) had viable tumor in the retroperitoneal specimen. All 4 patients who underwent post-chemotherapy retroperitoneal lymph node dissection and aortic replacement after induction chemotherapy alone have no evidence of disease. Only 1 of the 11 patients who received salvage chemotherapy with or without previous post-chemotherapy retroperitoneal lymph node dissection have no evidence of disease. Overall 33% of the patients have no evidence of disease. There were no graft related complications. Conclusions: Aortic resection at post-chemotherapy retroperitoneal lymph node dissection is justified based on therapeutic benefit and morbidity.

KW - Aorta

KW - Germinoma

KW - Lymph nodes

KW - Metastases

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=0035043425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035043425&partnerID=8YFLogxK

M3 - Article

C2 - 11342909

AN - SCOPUS:0035043425

VL - 165

SP - 1517

EP - 1520

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5 I

ER -